Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 January 2005Website:
http://eyepointpharma.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:02:01 GMTDividend
Analysts recommendations
Institutional Ownership
EYPT Latest News
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET.
WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced today that it has awarded non-statutory stock options to new employees as inducement awards, in line with NASDAQ Listing Rule 5635(c)(4), outside of the Company's 2023 Long-Term Incentive Plan.
EyePoint Pharmaceuticals Inc. saw its stock plummet by almost 30% in premarket trading on Monday following the announcement that its new retinal-disease treatment did not achieve the main objective in a clinical trial for patients with diabetic eye disease.
While the top- and bottom-line numbers for EyePoint Pharmaceuticals (EYPT) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing.
Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 31.3% upside potential for EyePoint Pharmaceuticals (EYPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 1(current)
What type of business is EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
What sector is EyePoint Pharmaceuticals in?
EyePoint Pharmaceuticals is in the Healthcare sector
What industry is EyePoint Pharmaceuticals in?
EyePoint Pharmaceuticals is in the Biotechnology industry
What country is EyePoint Pharmaceuticals from?
EyePoint Pharmaceuticals is headquartered in United States
When did EyePoint Pharmaceuticals go public?
EyePoint Pharmaceuticals initial public offering (IPO) was on 27 January 2005
What is EyePoint Pharmaceuticals website?
https://eyepointpharma.com
Is EyePoint Pharmaceuticals in the S&P 500?
No, EyePoint Pharmaceuticals is not included in the S&P 500 index
Is EyePoint Pharmaceuticals in the NASDAQ 100?
No, EyePoint Pharmaceuticals is not included in the NASDAQ 100 index
Is EyePoint Pharmaceuticals in the Dow Jones?
No, EyePoint Pharmaceuticals is not included in the Dow Jones index
When does EyePoint Pharmaceuticals report earnings?
The next expected earnings date for EyePoint Pharmaceuticals is 02 August 2024